Gross Profit Trends Compared: Novartis AG vs Halozyme Therapeutics, Inc.

Pharma Giants: Novartis vs Halozyme Profit Trends

__timestampHalozyme Therapeutics, Inc.Novartis AG
Wednesday, January 1, 20145260200036289000000
Thursday, January 1, 201510581200032983000000
Friday, January 1, 201611348500031916000000
Sunday, January 1, 201728546100032960000000
Monday, January 1, 201814172600034759000000
Tuesday, January 1, 201915044600034252000000
Wednesday, January 1, 202022422700034777000000
Friday, January 1, 202136189700037010000000
Saturday, January 1, 202252081200036342000000
Sunday, January 1, 202363689200034188000000
Monday, January 1, 202485590700038895000000
Loading chart...

Data in motion

Gross Profit Trends: Novartis AG vs Halozyme Therapeutics, Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis compares the gross profit trends of two significant players: Novartis AG and Halozyme Therapeutics, Inc., from 2014 to 2023.

Novartis AG, a global healthcare giant, consistently reported substantial gross profits, peaking in 2021 with approximately $37 billion. However, a slight decline was observed in 2023, with profits around $34 billion. In contrast, Halozyme Therapeutics, Inc., a smaller yet innovative company, demonstrated impressive growth. Starting with a modest $52 million in 2014, Halozyme's gross profit surged by over 1,100% to $637 million in 2023.

This stark contrast highlights the dynamic nature of the industry, where established giants and emerging innovators coexist, each contributing uniquely to the sector's growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025